DEAE 52 cellulose 9013-34-7
3 Inquiries
150812-12-7
pharmaceutical grade
99%
SHANGHAI
Ipure
25kg/Cardboard Drum
Yes
2026-01-26
pharmaceutical intermediates,chemical
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferencePurple SolidChEBI: A substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults.Retigabine was approved in March 2011 by the European Commission for the adjunctive treatment of partial-onset seizures in adults who have epilepsy; in June 2011, the U.S. FDA approved the same drug, known in the United States as ezogabine. Retigabine
Ezogabine is a substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults. It has a role as an anticonvulsant and a potassium channel modulator. It is a carbamate ester, an organofluorine compound, a substituted aniline and a secondary amino compound. It derives from a benzene-1,2,4-triamine.|Ezogabine is a DEA Schedule V controlled substance. Substances in the DEA Schedule V have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.|Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.|Ezogabine is a Potassium Channel Opener. The mechanism of action of ezogabine is as a Potassium Channel Opener.|Ezogabine, which is known as retigabine in Europe, is a unique anticonvulsant used largely as an adjunctive agent in the treatment of partial seizures. Therapy with ezogabine has not been associated with serum aminotransferase elevations, and clinically apparent liver injury from ezogabine has yet to be reported and must be rare, if it occurs at all.Basic Info-
Product Name:
Retigabine
Other Name:Carbamic acid,N-[2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-,ethyl ester;Carbamic acid,[2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-,ethyl ester;Ethyl [2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]carbamate;D 23129;Retigabine;Ezogabine;WAY 143841;GW 582892X;GKE 841;Trobalt;Potiga;[2-Amino-4-(4-fluoro-benzylamino)-phenyl]-carbamic acid ethyl ester
CAS No.:150812-12-7
Molecular Formula:C16H18FN3O2
InChIKeys:InChIKey=PCOBBVZJEWWZFR-UHFFFAOYSA-N
Molecular Weight:303.3314232
Exact Mass:303.33
EC Number:200-835-2
UNII:12G01I6BBU
DEA Code Number:2779
DSSTox ID:DTXSID40164615
Color/Form:White to slightly colored crystalline powder
ATC Code:N03AX21|N - Nervous system
Categories:
Characteristics-
PSA:
76.4
XLogP3:3.57 (est)
Appearance:white to light brown
Density:1.307±0.06 g/cm3(Predicted)
Melting Point:138-145 deg C
Boiling Point:430.0±45.0 °C(Predicted)
Flash Point:2℃
Refractive Index:1.656
Water Solubility:DMSO: >15mg/mL
Storage Conditions:room temp
Vapor Pressure:1.3X10-7 mm Hg at 25 deg C (est)
Odor:Odorless
Taste:Tasteless
Henrys Law Constant:Henry's Law constant = 8.93X10-10 atm-cu m/mol at 25 °C (est)
Dissociation Constants:10.8|pKa = 3.7 (basic)|pKa = 10.8
Experimental Properties:Non-hygroscopic|Hydroxyl radical reaction rate constant = 2.1X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H410 Very toxic to aquatic life with long lasting effects
Precautionary statement(s) Prevention P273 Avoid release to the environment.
Response P391 Collect spillage.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
pharmaceutical intermediates,chemical
-
Location:
Company Office Address: Room 1508, 15/F, Yate Centre Office Tower 2, 625 Nathan Road, Mong Kok, Hong Kong
-
Payment Terms:
TT against copy of documents,D/P,L/C,O/A,100% TT in advance
-
Average lead Time:
10 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted
Australia
Retigabine
1 KG Mar 23, 2026
United States
WAY-31660
500 MG Jul 25, 2026
United States
Retigabine
30 G Jan 30, 2025 Post an enquiry for this product
More from this Seller
-
-
-
3-Methyl-10-ethyl-Deazaflavin 59997-14-7 99% purity . top quality
pharmaceutical grade / 99%
-
-
-
-
Sodium polyacrylate9003-04-7
pharmaceutical grade / 99%
-
-
-
-
Methyl myristate124-10-7
pharmaceutical grade / 99%
-
-
-
-
CARDAMONIN18956-16-6
pharmaceutical grade / 99%
-
-
-
-
Dibutyl maleate105-76-0
pharmaceutical grade / 99%
$1/G FOB
-
-
-
-
2-Fluoroethylamine hydrochloride .460-08-2
pharmaceutical grade / 99%
-